1/ Given the recent results from @drdavidpalma and colleagues, the question has been raised regarding the rationale of randomizing oligometastatic pts without SABR in light of these results. As noted by Bob Timmerman in his ASTRO discussion, the data are jaw-dropping

RT @AlexisChidi: This #LungCancerAwarenessMonth join my colleagues @MSK_Thoracic @MSKCancerCenter @AmLungCSI in sharing this important mess…

@EChrisDee @PCF_Science @DRathkopf @seanmmcbride @DrPaulNguyen @BrandonMahal @DrVMuralidhar Really proud of you @EChrisDee.

@DrewMoghanaki @NiuSanford Drew was amazing and as usual the greatest of patient advocates.

@DrewMoghanaki Uh, theoretical?

@imrtlee @CJTsaiMDPhD @MSKCancerCenter @MSK_RadOnc @AMFShepherd @simonpowell213 @JYangMDPhD @ErinGillespieMD @gerryhanna Agree. Simple, elegant, and effective.

@drolihealth @HenningWillers @IJROBP @kenwestover @BobTimmermanMD @SalmaJabbour1 It was IO concurrent with radiation alone. The chemotherapy had been dropped.

RT @NRGonc: Episode 2 of "The NRG Podcast" is now available on Spotify, Apple Podcasts, and YouTube! Be sure to follow us for future conte…

RT @NRGonc: 👀 August 15th!

RT @NRGonc: Coming soon! Episode 2 of "The NRG Podcast" is heading your way. If you haven't already, follow us on Spotify or Apple Podcasts…

@DrSanjayPopat @fifimcdrmh Amazing time with @DrSanjayPopat and wife Sejal. Thanks for being such great hosts in London to our family. Hope to see you all soon again in person, perhaps across the pond.

@jryckman3 @CJTsaiMDPhD @MSK_RadOnc @NRGonc @ScottBratman @_ShankarSiva @drdavidpalma @KHigginsMD @DrPOGaudreau @sgswisher That data was captured as was more information which is being worked through. NRG LU002 will give us more insight as we do the planned translational studies and subset analyses - including ctDNA evaluations, QoL, oligoinduced vs oligopersistent cohorts, etc.

RT @NRGonc: Are you at #ASCO24? Today kicks off the first of many NRG presentations at ASCO this year. Dr. Iyengar will present on NRG-LU00…

@drdavidpalma @BrendonStilesMD Trailers give away too much information these days. All basic data will be revealed May 31st afternoon at ASCO Metastatic Lung Oral Session.

RT @TimRebbeck: This a sad day for the #cancer community, as @NCI is forced to make funding cuts: “Halfway into fiscal year 2024, NCI offi…

@rweichselbaum @DrewMoghanaki @SimonLo21054188 @the_RSS @DrAlexLouie @DrCorreaRO @drdavidpalma You are 100% correct @rweichselbaum. We are at a crossroads. It will take multimodal data to infer metastatic trajectories on individual patient levels to optimize local and systemic therapy integration. In nsclc this now applies to stages 1-4. We look to ur continued leadership.

@DrewMoghanaki @SimonLo21054188 @the_RSS @rweichselbaum @DrAlexLouie @DrCorreaRO @drdavidpalma I guess hindsight is 20/20. Didn’t stop everyone from cheering on RPh2 studies based on cross sectional, non-biologic numeric determinants of metastatic trajectories. Or still using the practice. Lessons learned. New data being generated.

@jillfeldman4 @fumikochino @Mat_Guc @ASTRO_org @jillfeldman4 the honor was ours. You have paved a new path for the critical role that survivors, patient advocates, and even care givers should have on these guidelines committees. This input is most critical to the success of our treatment of current and future pts.

RT @cancerGRACE: This live, virtual, interactive patient education event includes presentations and panel discussions covering general subj…

RT @EChrisDee: 📜 In @JCOOP_ASCO, we explore disparities in stage at presentation among #Hispanic #LatinX pts w #lung #cancer 🙏 @NishwantS…

@FordePatrick @maraantonoff @StephenVLiu @DrJNaidoo @CJTsaiMDPhD @PatelOncology @DrRiyazShah 5) Finally, I will say we will work hard to complete all the analyses of the study to provide granularity regarding outcomes to inform future patient discussions, trials, and therapy decision-making. But, as systemic therapy gets better, only subsets will benefit from local tx.